FrancophonIA/ELRC3.0 huggingface dataset:
English: The following adverse reactions which may be causally related to the administration of Viramune have been reported.
Croatian: Prijavljeno je da sljedeće nuspojave mogu biti uzročno povezane s primjenom Viramunea.
English: The interaction data is presented as geometric mean value with 90% confidence interval (90% CI) whenever these data were available.
Croatian: Podaci o interakcijama prikazani su, ako su dostupni, kao geometrijska srednja vrijednost s 90%-tnim intervalom pouzdanosti (90% CI), NO = Nije određeno, ↑ = Povećano, ↓ = Smanjeno,  = Bez učinka
English: The interaction data is presented as geometric mean value with 90% confidence interval (90 % CI) whenever these data were available.
Croatian: Podaci o interakcijama prikazani su, ako su dostupni, kao geometrijska srednja vrijednost s 90% -tnim intervalom pouzdanosti (90% CI), NO = Nije određeno, ↑ = Povećano, ↓ = Smanjeno,  = Bez učinka
English: Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets (see section
Croatian: Viramune je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih, adolescenata i djece s HIV-1 infekcijom u dobi tri i više godina koji mogu gutati tablete (vidjeti dio
English: Metabolite 14-OH clarithromycin AUC  1.42 (1.16-1.73) Metabolite 14-OH clarithromycin Cmin  0 (0.68-1.49) Metabolite 14-OH clarithromycin Cmax  1.47 (1.21-1.80)
Croatian: Metabolit 14-OH klaritromicin AUC Metabolit 14-OH klaritromicin Cmin Metabolit 14-OH klaritromicin Cmax
English: Maintenance packs:
Croatian: Pakiranja za održavanje liječenja:
English: If a dose is recognized as missed within 12 hours of when it was due, the patient should take the missed dose as soon as possible.
Croatian: U slučaju propuštene doze, ako je prošlo manje od 12 sati od kada je propuštena, bolesnik treba uzeti propuštenu dozu čim je prije moguće.
English: - muscle or joint pain - general feelings of illness - abdominal pain - hypersensitivity (allergic) reactions - inflammation of the liver (hepatitis) - if you have severe liver disease - if you have had to stop Viramune treatment in the past because of changes in your liver function - if you are taking a medicine containing the herbal substance St. John's Wort (Hypericum perforatum).
Croatian: - opći osjećaj bolesti - bol u trbuhu - reakcije preosjetljivosti (alergijske reakcije) - upala jetre (hepatitis) - ako imate tešku bolest jetre - ako ste morali prekinuti liječenje Viramuneom zbog promjena u funkciji jetre - ako uzimate lijekove koji sadrže biljnu tvar gospinu travu (Hypericum perforatum).
English: Iron oxide yellow
Croatian: Pneumocystis jirovecii.
English: Height
Croatian: visina
English: If a dose is recognized as missed within 8 hours of when it was due, the patient should take the missed dose as soon as possible.
Croatian: U slučaju propuštene doze, ako je prošlo manje od 8 sati od kada je trebala biti uzeta, bolesnik treba uzeti propuštenu dozu čim je prije moguće.
English: INFORMATION IN BRAILLE viramune 400 mg prolonged-release tablets
Croatian: 16. PODACI NA BRAILLEOVOM PISMU viramune 400 mg tablete s produljenim oslobađanjem
English: Raltegravir and Viramune can be coadministered without dose adjustments.
Croatian: Raltegravir i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: VERxVE (study 1100.1486) is a phase 3 study in which treatment-naïve patients received Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Croatian: VERxVE (ispitivanje 1100.1486) je ispitivanje faze 3 u kojem su prethodno neliječeni bolesnici primali Viramune 200 mg s trenutnim oslobađanejm jednom dnevno u trajanju od14 dana, a zatim su bili randomizirani na Viramune 200 mg s trenutnim oslobađanjem dvaput dnevno ili Viramune 400 mg s produljenim oslobađanjem jednom dnevno.
English: Serum levels of nevirapine can be reduced by concomitant use of the herbal preparation St. John's Wort (Hypericum perforatum).
Croatian: Razina nevirapina u serumu može se sniziti uz istodobnu primjenu biljnih pripravka gospine trave (Hypericum perforatum) zbog indukcijskog učinka lijeka gospine trave na metabolizirajuće enzime i/ili transportne proteine.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 200 mg of nevirapine (as anhydrous)
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 200 mg nevirapina (u bezvodnom obliku)
English: - general swelling - shortness of breath - muscle or joint pain - general feelings of illness - abdominal pain - hypersensitivity (allergic) reactions - inflammation of the liver (hepatitis) - if you have severe liver disease - if you have had to stop Viramune treatment in the past because of changes in your liver function - if you are taking a medicine containing the herbal substance St. John's Wort (Hypericum perforatum).
Croatian: - nedostatak zraka - bol u mišićima ili zglobovima - opći osjećaj bolesti - bol u trbuhu - reakcije preosjetljivosti (alergijske reakcije) - upala jetre (hepatitis) - ako imate tešku bolest jetre - ako ste morali prekinuti liječenje Viramuneom zbog promjena u funkciji jetre - ako uzimate lijekove koji sadrže biljnu tvar gospinu travu (Hypericum perforatum).
English: Herbal preparations containing St.
Croatian: BILJNI PRIPRAVCI Gospina trava
English: The 200 mg once daily dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Croatian: Režim doziranja od 200 mg jednom dnevno ne smije se nastaviti dulje od 28 dana, već u takvom slučaju treba odrediti alternativno liječenje zbog mogućeg rizika nedostatne izloženosti lijeku i razvoja rezistencije.
English: In the multinational 2NN study, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females.
Croatian: Podaci za 1 077 bolesnika (391 žena) uključenih umultinacionalnu studiju 2NN iskorišteni su za populacijsku farmakokinetsku analizu.
English: Patients should be instructed to seek medical attention promptly if these occur.
Croatian: U slučaju pojave navedenih simptoma, bolesnike je potrebno upozoriti da odmah potraže liječničku pomoć.
English: Treatment-naïve patients
Croatian: Prethodno neliječeni bolesnici
English: Lead-in dosing with Viramune 200 mg tablets or Viramune 50 mg/5 ml oral suspension (first 14 days): All paediatric patients should initiate therapy with 150 mg/m2 (calculated using the Mosteller formula)
Croatian: Uvodno doziranje s Viramune 200 mg tabletama ili Viramune 50 mg/5 ml oralnom suspenzijom (prvih 14 dana):
English: For patients already on a regimen of Viramune immediate-release twice daily who switch to Viramune prolonged-release once daily there is no need for a change in their monitoring schedule.
Croatian: Nema potrebe za promjenom režima praćenja za bolesnike koji su već bili na Viramuneu s trenutnim oslobađanjem dvaput dnevno, a koji se prebace na Viramune s produljenim oslobađanjem jednom dnevno.
English: Darunavir and Viramune can be coadministered without dose adjustments.
Croatian: Darunavir i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Common (may affect up to 1 in 10 people): - rash - fever - headache - abdominal pain - feeling sick (nausea) - loose stools (diarrhoea) - feeling tired (fatigue)
Croatian: Često (može se javiti u do 1 na 10 osoba): - osip - vrućica - glavobolja - bol u trbuhu - mučnina - mekana stolica (proljev) - osjećaj umora (umor)
English: Didanosine and Viramune can be coadministered without dose adjustments.
Croatian: Didanozin i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: In study 1100.1486 (VERxVE) treatment-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Croatian: U ispitivanju 1100.1486 (VERxVE), prethodno neliječeni bolesnici primali su uvodnu dozu Viramunea 200 mg s trenutnim oslobađanjem jednom dnevno u trajanju od 14 dana, a zatim su bili randomizirani za Viramune 200 mg s trenutnim oslobađanjem dvaput dnevno ili Viramune 400 mg s produljenim oslobađanjem jednom dnevno.
English: INFORMATION IN BRAILLE viramune 100 mg prolonged-release tablets
Croatian: 16. PODACI NA BRAILLEOVOM PISMU viramune 100 mg tablete s produljenim oslobađanjem
English: Uncommon liver function test abnormal (alanine aminotransferase increased; transaminases increased; aspartate aminotransferase increased; gamma-glutamyltransferase increased; hepatic enzyme increased; hypertransaminasaemia), blood phosphorus decreased, blood pressure increased
Croatian: Manje često abnormalni testovi jetrene funkcije (povišena alanin-aminotransferaza; povišene transaminaze; povišena aspartat-aminotransferaza; povišena gamaglutamiltransferaza; povišeni jetreni enzimi; hipertransaminazemija), snižene vrijednosti fosfora u krvi, povišeni krvni tlak
English: - St. John's Wort (Hypericum perforatum, medicine to treat depression) - rifampicin (medicine to treat tuberculosis) - rifabutin (medicine to treat tuberculosis) - macrolides e.g. clarithromycin (medicine to treat bacterial infections) - fluconazole (medicine to treat fungal infections) - ketoconazole (medicine to treat fungal infections) - itraconazole (medicine to treat fungal infections) - methadone (medicine used for treatment of opiate addicts) - warfarin (medicine to reduce blood clotting) - hormonal contraceptives (e.g. the “pill”) - atazanavir (another medicine to treat HIV-infection) - lopinavir/ritonavir (another medicine to treat HIV-infection) - fosamprenavir (another medicine to treat HIV-infection) - efavirenz (another medicine to treat HIV-infection) - etravirine (another medicine to treat HIV-infection) - rilpivirine (another medicine to treat HIV-infection) - delavirdine (another medicine to treat HIV-infection) - zidovudine (another medicine to treat HIV-infection) - boceprevir (medicine to treat hepatitis C) - telaprevir (medicine to treat hepatitis C) - elvitegravir/cobicistat (another medicine to treat HIV-infection)
Croatian: - gospinu travu (Hypericum perforatum, lijek za liječenje depresije) - rifampicin (lijek za liječenje tuberkuloze) - rifabutin (lijek za liječenje tuberkuloze) - makrolidi, npr. klaritromicin (lijek za liječenje bakterijskih infekcija) - flukonazol (lijek za liječenje gljivičnih infekcija) - ketokonazol (lijek za liječenje gljivičnih infekcija) - itrakonazol (lijek za liječenje gljivičnih infekcija) - metadon (lijek koji se primjenjuje u liječenju opijatskih ovisnika) - varfarin (lijek za smanjenje zgrušavanja krvi) - hormonske kontraceptive (npr. “pilule”) - atazanavir (drugi lijek za liječenje HIV-infekcije) - lopinavir/ritonavir (drugi lijek za liječenje HIV-infekcije) - fosamprenavir (drugi lijek za liječenje HIV-infekcije) - efavirenz (drugi lijek za liječenje HIV-infekcije) - etravirin (drugi lijek za liječenje HIV infekcije) - rilpivirin (drugi lijek za liječenje HIV infekcije) - delavirdin (drugi lijek za liječenje HIV infekcije) - zidovudin (drugi lijek za liječenje HIV-infekcije) - boceprevir (lijek za liječenje hepatitisa C) - telaprevir (lijek za liječenje hepatitisa C) - elvitegravir/kobicistat (drugi lijek za liječenje infekcije HIV-om)
English: 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 46 µg/ml (as targeted from adult data).
Croatian: Doziranje 150 mg/m2 dvaput dnevno (nakon uvodna dva tjedna s dozom od 150 mg/m2 jednom dnevno ) omogućilo je prosječne koncentracije na kraju dozirnog intervala u rasponu od 4 do 6 µg/ml (kako je i planirano, s obzirom na podatke od odraslih).
English: Hepatobiliary disorders
Croatian: propilparahidroksibenzoat,
English: Table 2: Outcomes at week 48 in study 1100.1486*
Croatian: Tablica 3: Ishodi nakon 48 tjedana u ispitivanju 1100.1486 prema početnom virusnom opterećenju*
English: Viramune 100 mg prolonged-release tablets nevirapine
Croatian: Viramune 100 mg tablete s produljenim oslobađanjem nevirapin
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each prolonged-release tablet contains 400 mg of nevirapine (as anhydrous)
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta s produljenim oslobađanjem sadrži 400 mg nevirapina (u bezvodnom obliku)
English: Viramune 400 mg prolonged-release tablets nevirapine
Croatian: Viramune 400 mg tablete s produljenim oslobađanjem nevirapin
English: If it has been more than 8 hours since the dose was due only take the next dose at the usual time.
Croatian: Ako je prošlo više od 8 sati, treba uzeti sljedeću dozu u uobičajeno vrijeme.
English: Atazanavir/ritonavir 300/100 mg QD 400/100 mg QD
Croatian: Inhibitori proteaza Atazanavir/ritonavir 300/100 mg 1x/dan 400/100 mg 1x/dan
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each prolonged-release tablet contains 100 mg of nevirapine (as anhydrous)
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta s produljenim oslobađanjem sadrži 100 mg nevirapina (u bezvodnom obliku)
English: Saquinavir/ritonavir and Viramune can be co-administered without dose adjustments.
Croatian: Sakvinavir/ritonavir i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Viramune 100 mg prolonged-release tablets should not be used by adults.
Croatian: Odrasle osobe ne smiju primjenjivati Viramune 100 mg tablete s produljenim oslobađanjem.
English: Tipranavir and Viramune can be coadministered without dose adjustments.
Croatian: Tipranavir i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: If you notice you missed a dose within 12 hours of when it was due, take the missed dose as soon as possible.
Croatian: Ako primijetite da ste propustili dozu unutar 8 sati od vremena kad ste ju trebali uzeti, uzmite propuštenu dozu čim je prije moguće.
English: Cimetidine and Viramune can be coadministered without dose adjustments.
Croatian: Cimetidin i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: In study 1100.1486 (VERxVE) antiretroviral-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days (n=1068) and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Croatian: U ispitivanju 1100.1486 (VERxVE) “neliječeni” bolesnici antiretrovirusnom terapijom primali su uvodnu dozu Viramunea 200 mg s trenutnim oslobađanjem jednom dnevno tijekom 14 dana (n=1068) te su zatim ranodmizirani za ili Viramune 200 mg s trenutnim oslobađanjem dvaput dnevno ili Viramune 400 mg s produljenim oslobađanjem jednom dnevno.
English: Changes of body fat may occur in patients receiving combination antiretroviral therapy.
Croatian: U bolesnika koji primaju kombiniranu retrovirusnu terapiju može doći do promjena tjelesnih masnoća.
English: Gastrointestinal disorders Common abdominal pain, nausea, diarrhoea Uncommon vomiting
Croatian: Poremećaji probavnog sustava Često bol u abdomenu, mučnina, proljev Manje često povraćanje
English: You are at greatest risk of such a reaction during the first 6 weeks of treatment.
Croatian: Tijekom prvih 6 tjedana liječenja rizik od takvih reakcija je najveći.
English: Fosamprenavir/ritonavir and Viramune can be co-administered without dose adjustments
Croatian: Fosamprenavir/ritonavir i Viramune mogu se primjenjivati istodobno bez prilagodbe doze.
English: NAME OF THE MEDICINAL PRODUCT Viramune 400 mg prolonged-release tablets
Croatian: NAZIV LIJEKA Viramune 400 mg tablete s produljenim oslobađanjem2.
English: Telbivudine and Viramune may be coadministered without dose adjustments.
Croatian: Telbivudin i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
English: As explained in 'Warnings and precautions', above, your doctor will monitor you with liver tests or for undesirable effects such as rash.
Croatian: Kao što je objašnjeno u prethodnom dijelu «Upozorenja i mjere opreza», liječnik će pratiti
English: Do not use this medicine after the expiry date which is stated on the carton and on the blister or bottle after “EXP”.
Croatian: Ovaj lijek se ne smije upotrijebiti upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru ili bočici iza oznake „EXP”.
English: Ribavirin and Viramune may be coadministered without dose adjustments.
Croatian: Ribavirin i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
English: Lamivudine and Viramune can be coadministered without dose adjustments.
Croatian: Lamivudin i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
English: Viramune prolonged-release tablets have not been studied in patients with renal dysfunction and Viramune immediate-release should be used.
Croatian: Viramune tablete s produljenim oslobađanjem nisu ispitivane na bolesnicima s disfunkcijom bubrega te stoga treba primjenjivati Viramune s trenutnim oslobađanjem.
English: In the multinational 2NN study with Viramune immediate-release, a population pharmacokinetic substudy of 1077 patients was performed that included 391 females.
Croatian: Podaci za 1 077 bolesnika, od kojih 391 žena, uključenih u multinacionalnu studiju 2NN s Viramuneom s trenutnim oslobađenjem iskorišteni su za populacijsku farmakokinetsku analizu.
English: Women have a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8 % versus 2.2 %), and treatment-naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine.
Croatian: Bolesnici obaju spolova prethodno neliječeni, a imaju detektibilnu HIV-1 RNK u plazmi i povišen broj CD4 na početku terapije nevirapinom imaju viši rizik simptomatskog oštećenja jetre uz nevirapin.
English: You may experience fatigue when taking Viramune.
Croatian: Tijekom uzimanja Viramunea možete osjetiti umor.
English: Maraviroc and Viramune can be coadministered without dose adjustments.
Croatian: Maravirok i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Adefovir and Viramune may be coadministered without dose adjustments.
Croatian: Adefovir i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
English: Common (may affect up to 1 in 10 people): - rash - headache - abdominal pain - feeling sick (nausea) - inflammation of the liver (hepatitis) - feeling tired (fatigue) - abnormal liver function tests - fever - vomiting - loose stools (diarrhoea)
Croatian: Često (može se javiti u do 1 na 10 osoba): - osip - glavobolja - bol u trbuhu - mučnina - upala jetre (hepatitis) - osjećaj umora (umor) - abnormalni nalazi jetrenih testova - vrućica - povraćanje - mekana stolica (proljev)
English: The once daily Viramune immediate-release lead-in dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Croatian: Jednokratni dnevni režim doziranja Viramunea s trenutnim oslobađanjem u uvodnom razdoblju ne smije trajati dulje od 28 dana, kada je potrebno uvesti alternativno liječenje zbog mogućeg rizika od nedostatne ekspozicije lijeku i razvoja rezistencije.
English: Rifabutin and Viramune can be co-administered without dose adjustments.
Croatian: Rifabutin i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Because of the risk of increased
Croatian: Ako ste uzeli više
English: Ritonavir and Viramune can be coadministered without dose adjustments.
Croatian: Ritonavir i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Each tablet contains less than 1 mmol sodium (23 mg), that is to say essentially ‘sodium-free'.
Croatian: Jedna tableta sadrži manje od 1 mmol (23 mg) natrija, tj. zanemarive količine natrija.
English: Prolonged-release tablet
Croatian: Tablični prikaz nuspojava
English: Viramune prolonged-release tablets have not been evaluated in patients with hepatic impairment and Viramune immediate-release should be used.
Croatian: Viramune tablete s produljenim oslobađanjem nisu ocjenjivane na bolesnicima s oštećenjem jetre, te se stoga treba primjenjivati Viramune s trenutnim oslobađanjem.
English: ANTITHROMBOTICS Warfarin
Croatian: Sakvinavir/ritonavir
English: Shake the bottle gently Fit (by first pressing and then screwing) the adapter onto the open bottle neck Insert the syringe into the adapter Invert the bottle Withdraw the required dose volume The bottle can be kept sealed with the flexible lid of the adapter.
Croatian: Namjestite (prvo pritiskom i onda zavrtanjem) nastavak na otvoreno grlo boce
English: - treatment-naïve patients with higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³) - pre-treated patients with detectable HIV-1 plasma viral load and higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³)
Croatian: - bolesnici prethodno neliječeni antiretrovirusnim lijekovima, s povišenim brojem CD4 stanica na početku terapije Viramuneom (žene s više od 250 stanica/mm
English: - If you get any side effects talk to your doctor or pharmacist.
Croatian: - Ako primjetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
English: Interferons and Viramune may be coadministered without dose adjustments.
Croatian: Interferoni i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
English: Stavudine and Viramune can be coadministered without dose adjustments.
Croatian: Stavudin i Viramune mogu se istodobno primjenjivati bez prilagodbe doze.
English: Clear low density polyethylene bottle-syringe adapter.
Croatian: Prozirni nastavak za bocu-štrcaljku od polietilena niske gustoće.
English: In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms.
Croatian: Abakavir nije inhibirao izoforme citokroma P450 u mikrosomima ljudske jetre.
English: Baseline (mean) n=503
Croatian: Početne vrijednosti (srednja vrijednost) n=503
English: Viramune and abacavir may be coadministered without dose adjustments.
Croatian: Viramune i abakavir se mogu istodobno primjenjivati bez prilagodbe doze.
English: Viramune prolonged-release tablets have not been studied in patients with hepatic impairment and Viramune immediate-release should be used.
Croatian: Viramune tablete s produljenim oslobađanjem nisu ispitivane na bolesnicima s oštećenjem jetre te se treba primjenjivati Viramune s trenutnim oslobađanjem.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/006
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/055/006
English: Table 3: Outcomes at 48 weeks in study 1100.1486 by baseline viral load* Number with response/total number (%) Difference in % (95 % CI)
Croatian: Tablica 2: Ishodi nakon 48 tjedana u ispitivanju 1100.1486* Viramune s trenutnim oslobađanjem n=506
English: Once daily maintenance dosing with Viramune prolonged-release tablets (after the lead-in): The recommended oral doses for paediatric patients based upon their BSA are described in the table below.
Croatian: Preporučene peroralne doze za pedijatrijske bolesnike na osnovi njihove BSA opisane su u donjoj tablici.
English: Do not use this medicine after the expiry date which is stated on the carton and on the blister after “EXP”.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „EXP”.
English: 200 mg QD
Croatian: 600 mg 1xsvaki dan
English: Patients should be instructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
Croatian: Bolesnike također treba upozoriti da se u slučaju pojave osipa, tijekom 14.dnevnog uvodnog razdoblja liječenja Viramuneom s trenutnim oslobađanjem, ne smiju uvoditi Viramune tablete s produljenim oslobađanjem dok se ne riješi osip.